Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.

The Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E. is running a large body of research in neoplasms, with a strong focus on breast cancer, lung cancer, gastrointestinal cancers, melanoma, and urothelial cancer. These studies are mainly designed to test new treatment options and compare them with current standards to improve survival and disease control.

• Advanced non-small cell lung cancer and small cell lung cancer
• Breast cancer, including hormone receptor-positive, HER2-negative, and triple-negative disease
• Gastric, gastroesophageal junction, and esophageal cancers
• Melanoma, head and neck cancer, and other advanced solid tumors

Much of the work at this Porto site centers on evaluating whether newer targeted or immune-based approaches can improve outcomes for people with difficult-to-treat cancers.

Another major research area is hemic and lymphatic diseases, especially acute leukemias, lymphomas, multiple myeloma, and related disorders. The trials in this field are focused on improving response rates, extending remission, and finding better options for patients whose disease has returned or stopped responding to prior therapy.

• Acute myeloid leukemia and acute lymphoblastic leukemia
• Diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia
• Multiple myeloma in newly diagnosed and relapsed settings
• Myeloproliferative neoplasms such as polycythemia vera and essential thrombocythemia

Research here also includes studies of long-term treatment benefit and safety, reflecting the site’s broad experience in medical oncology and blood cancers.

The site has a strong portfolio of biomarker-guided oncology studies that match treatment to tumor features such as gene mutations or protein expression. These trials aim to improve the accuracy of treatment selection and help identify which patients are most likely to benefit from a given therapy.

• EGFR, KRAS G12C, ALK, RET, and NTRK-driven cancers
• HER2-expressing and HER2-low tumors
• PD-L1-positive cancers and other immune-related biomarkers
• PIK3CA, BRCA, and other molecularly defined disease groups

These studies highlight a growing emphasis on personalized cancer care at Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E., with research aimed at making treatment more targeted and effective.

A substantial part of the research landscape involves immunotherapy and combination strategies that seek to strengthen the body’s anti-cancer response. The trials cover a wide range of tumors and are designed to improve disease control, delay progression, and test whether combining treatments offers better results than standard approaches alone.

• Checkpoint inhibitor-based treatment strategies
• Novel immunotherapy combinations for lung, breast, and head and neck cancers
• Adjuvant and neoadjuvant immune-based approaches
• Studies evaluating whether adding immune therapy can improve survival or reduce recurrence

This area shows the site’s active role in advancing newer immune-based cancer treatments across several major tumor types.

The research program also includes important work in pediatric oncology, particularly acute lymphoblastic leukemia and acute myeloid leukemia in children and adolescents. In addition, the site participates in follow-up studies of gene-modified T cells, supporting long-term monitoring of innovative cellular therapies.

• Childhood acute lymphoblastic leukemia and infant leukemia
• Pediatric acute myeloid leukemia
• Gene-modified T-cell follow-up research
• Studies focused on treatment outcomes, safety, and long-term benefit

These trials reflect a commitment to improving outcomes for younger patients while also tracking the lasting effects of advanced therapies.

Beyond the major disease groups, the site is also involved in trials for prostate cancer, ovarian cancer, bladder cancer, renal cell carcinoma, and soft tissue sarcoma. The purpose of this research is to assess new treatment options, improve disease control, and support patients with cancers that are often advanced or recurrent.

• Metastatic castration-resistant prostate cancer
• Ovarian and gastrointestinal stromal tumors
• Non-muscle-invasive bladder cancer and advanced urothelial cancer
• Renal cell carcinoma, leiomyosarcoma, and other rare solid tumors

These studies add breadth to the trial portfolio at this hospital-based research site, showing activity across both common and less frequent cancers.